Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease
The DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.
Abstract
Gene dosage of the apolipoprotein E (APOE) epsilon 4 allele is a major risk factor for familial Alzheimer disease (AD) of late onset (after age 60). Here we studied a large series of 115 AD case subjects and 243 controls as well as 150 affected and 197 unaffected members of 66 AD families. Our data demonstrate a protective effect of the epsilon 2 allele, in addition to the dose effect of the epsilon 4 allele in sporadic AD. Although a substantial proportion (65%) of AD is attributable to the presence of epsilon 4 alleles, risk of AD is lowest in subjects with the epsilon 2/epsilon 3 genotype, with an additional 23% of AD attributable to the absence of an epsilon 2 allele. The opposite actions of the epsilon 2 and epsilon 4 alleles further support the direct involvement of APOE in the pathogenesis of AD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Common variants of the apolipoprotein E gene (APOE) influence the risk of Alzheimer’s disease: APOE4 is linked to high risk, APOE3 is considered to confer a neutral risk, and APOE2 is associated with relative protection.2–5”
From APOE3 Christchurch Heterozygosity and Autosomal Dominant Alzheimer’s Disease (2024) · cites this paper as [5]
Experimental — accuracy not yet measuredIn the citing paper
“APOE, the major susceptibility gene for late-onset AD, has three common alleles (APOE2, 3, and 4).”
From Resistance to autosomal dominant Alzheimer’s disease in an APOE3 Christchurch homozygote: a case report (2019) · cites this paper as [10]
In the citing paper
“Compared to the most common APOE3/3 genotype, which is considered neutral with regard to AD risk, APOE2 is associated with a lower AD risk and older age at dementia onset, and each additional copy of APOE4 is associated with a higher risk and younger age at onset.10”
From Resistance to autosomal dominant Alzheimer’s disease in an APOE3 Christchurch homozygote: a case report (2019) · cites this paper as [10]
In the citing paper
“Apolipoprotein E (APOE), the major susceptibility gene for late-onset Alzheimer’s disease (AD), has three common alleles (APOE2, 3, and 4), giving rise to six genotypes (APOE2/2, 2/3, 3/3, 2/4, 3/4, and 4/4).”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [2]
In the citing paper
“while the presence of one or two copies of the APOE2 allele is associated with a lower risk of Alzheimer’s dementia and an older mean age at dementia onset1–4.”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [2]
38 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Self-citationGoate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Self-citationStrittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268
Self-citationApolipoprotein E: Cholesterol Transport Protein with Expanding Role in Cell Biology
Mahley, R. W. (1988) · Science · doi:10.1126/science.3283935 · Cited by 4,028
Association of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
Self-citationDiagnosis of Alzheimer's Disease
Khachaturian, Z. S. (1985) · Archives of Neurology · doi:10.1001/archneur.1985.04060100083029 · Cited by 2,499
Schmechel, D. E., Saunders, A. M., Strittmatter, W. J., Crain, B. J., Hulette, C. M., Joo, S. H., Pericak-Vance, M. A., Goldgaber, D., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.20.9649 · Cited by 1,525
Self-citationStrittmatter, W. J., Weisgraber, K. H., Huang, D. Y., Dong, L. M., Salvesen, G. S., Pericak-Vance, M., Schmechel, D., Saunders, A. M., Goldgaber, D., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.17.8098 · Cited by 1,363
Self-citationThe Genetic Defect Causing Familial Alzheimer's Disease Maps on Chromosome 21
St George-Hyslop, P. H., Tanzi, R. E., Polinsky, R. J., Haines, J. L., Nee, L., Watkins, P. C., Myers, R. H., Feldman, R. G., Pollen, D., Drachman, D., et al. (1987) · Science · doi:10.1126/science.2880399 · Cited by 1,163
Self-citation
Research works printed but not linked: 2
- Cornoni-Huntley, J., Blazer, D.G., Service, C. & Farmer, M.E. in Established population for epidemiologic studies of the elderly. Volume II (eds Cornoni-Huntley, J. et al.) 1–7 (NIH publication 90–495, Bethesda, 1990).
- Rothman, K.J. Modern Epidemiology. 38–39, 76 (Little, Brown & Company, Boston, 1986).
Cited by
Items 301–400 of 1,029
Lane-Donovan, C., Wong, W. M., Durakoglugil, M. S., Wasser, C. R., Jiang, S., Xian, X., & Herz, J. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.1054-16.2016 · Cited by 115
“The more common ApoE3 allele is considered to be risk neutral, while the relatively rare ApoE2 allele appears to protect against AD (Corder et al., 1994).”
BackgroundHealth effects of aluminum: a critical review with emphasis on aluminum in drinking water
Nieboer, E., Gibson, B. L., Oxman, A. D., & Kramer, J. R. (1995) · Environmental Reviews · doi:10.1139/a95-002 · Cited by 115
Scott, W. K., Grubber, J. M., Conneally, P. M., Small, G. W., Hulette, C. M., Rosenberg, C. K., Saunders, A. M., Roses, A. D., Haines, J. L., & Pericak‐Vance, M. A. (2000) · The American Journal of Human Genetics · doi:10.1086/302828 · Cited by 120
“The presence of the APOE-4 allele increases risk and decreases age at onset of the disease, whereas the APOE-2 allele has a protective function (Corder et al. 1993, 1994).”
BackgroundSelf-citationReduced cerebrovascular reactivity in young adults carrying the APOE ε4 allele
Suri, S., Mackay, C. E., Kelly, M. E., Germuska, M., Tunbridge, E. M., Frisoni, G. B., Matthews, P. M., Ebmeier, K. P., Bulte, D. P., & Filippini, N. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.05.1755 · Cited by 112
“Conversely, the ε2 allele has been associated with lower risk of AD-related pathology, and therefore is believed to confer protection [6].”
BackgroundPetit, D., Fernández, S. G., Zoltowska, K. M., Enzlein, T., Ryan, N. S., O’Connor, A., Szaruga, M., Hill, E., Vandenberghe, R., Fox, N. C., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01518-6 · Cited by 120
“The APOE ε 2 allele has been found to lower AD risk and/or delay its onset [52–54].”
Marked regional differences of brain human apolipoprotein e expression in targeted replacement mice
Sullivan, P. M., Mace, B. E., Maeda, N., & Schmechel, D. E. (2004) · Neuroscience · doi:10.1016/j.neuroscience.2003.10.011 · Cited by 113
Self-citationAssociation Between Apolipoprotein E Genotype and Alzheimer Disease in African American Subjects
Graff-Radford, N. R., Green, R. C., Go, R. C. P., Hutton, M. L., Edeki, T., Bachman, D., Adamson, J. L., Griffith, P., Willis, F. B., Williams, M., et al. (2002) · Archives of Neurology · doi:10.1001/archneur.59.4.594 · Cited by 113
Self-citationEffect of APOE genotype on microvascular basement membrane in Alzheimer's disease
Salloway, S., Gur, T., Berzin, T., Zipser, B., Correia, S., Hovanesian, V, Fallon, J., Kuo-Leblanc, V, Glass, D., Hulette, C., et al. (2002) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(02)00288-5 · Cited by 113
Amiri, H., Saeidi, K., Borhani, P., Manafirad, A., Ghavami, M., & Zerbi, V. (2013) · ACS Chemical Neuroscience · doi:10.1021/cn4001582 · Cited by 113
Alternative splicing of mRNA in the molecular pathology of neurodegenerative diseases
Mills, J. D., & Janitz, M. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.10.030 · Cited by 136
Heffernan, A. L., Chidgey, C., Peng, P., Masters, C. L., & Roberts, B. R. (2016) · Journal of Molecular Neuroscience · doi:10.1007/s12031-016-0804-x · Cited by 113
“…risk 3–4 times, whereas homozygous ε4/ε4 carriers have an 8–12 times increased risk of developing AD compared with ε2 which has a protective effect (Corder et al. 1994; Verghese et al. 2011), and this risk is known to vary by demographic factors including sex and ethnicity Electronic…”
BackgroundMaezawa, I., Nivison, M., Montine, K. S., Maeda, N., & Montine, T. J. (2006) · The FASEB Journal · doi:10.1096/fj.05-5423fje · Cited by 113
“At least for AD, inheritance of APOE2 is associated with apparent neuroprotection, perhaps related to delayed onset of illness by many years (27).”
BackgroundContribution of APOE promoter polymorphisms to Alzheimer’s disease risk
Lambert, J. C., Araria-Goumidi, L., Myllykangas, L., Ellis, C., Wang, J. C., Bullido, M. J., Harris, J. M., Artiga, M. J., Hernandez, D., Kwon, J. M., et al. (2002) · Neurology · doi:10.1212/wnl.59.1.59 · Cited by 113
The Genetics of Alzheimer’s Disease
Barber, R. C. (2012) · Scientifica · doi:10.6064/2012/246210 · Cited by 101
“In contrast, individuals who carry the APOE 2 allele have a lower risk for Alzheimer’s disease relative to other genotypes [77].”
BackgroundRoses, A. D., Saunders, A. M., Huang, Y., Strum, J. C., Weisgraber, K. H., & Mahley, R. W. (2006) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500397 · Cited by 114
Self-citationReduction in DHA transport to the brain of mice expressing human APOE 4 compared to APOE 2
Vandal, M., Alata, W., Tremblay, C., Rioux‐Perreault, C., Salem, N., Calon, F., & Plourde, M. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12640 · Cited by 110
The Pathophysiology of Concussions in Youth
Shrey, D. W., Griesbach, G. S., & Giza, C. C. (2011) · Physical Medicine and Rehabilitation Clinics of North America · doi:10.1016/j.pmr.2011.08.002 · Cited by 140
“E 32 genotype is protective in chronic traumatic encephalopathy, as it seems to be in Alzheimer disease.(217) The implications of these findings support the theory that chronic traumatic encephalopathy, as well as Alzheimer disease, share a complex”
Down Syndrome: Advances in Molecular Biology and the Neurosciences
CAPONE, G. T. (2001) · Journal of Developmental & Behavioral Pediatrics · doi:10.1097/00004703-200102000-00007 · Cited by 110
“Gene dose for APOE E4 is correlated with both increased risk and earlier onset of AD, whereas the APOE E2 gene dose seems to confer some protective effect.(198) To determine whether this relationship holds true in DS, several studies have examined APOE allele frequency in adults with and without clinical symptoms of d…”
BackgroundPeng, Y., Gao, P., Shi, L., Chen, L., Liu, J., & Long, J. (2020) · Antioxidants & Redox Signaling · doi:10.1089/ars.2019.7763 · Cited by 110
“The APOE type 4 allele (APOE4) is the main genetic risk factor for sporadic AD (64), whereas the APOE2 genotype has been identified as a protective factor for late-onset sporadic AD (63).”
BackgroundPharmacogenomics in Alzheimer's Disease
Cacabelos, R. (2008) · Methods in Molecular Biology™ · doi:10.1007/978-1-59745-205-2_10 · Cited by 109
Fatty acids, lipid metabolism and Alzheimer pathology
Hooijmans, C. R., & Kiliaan, A. J. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.11.081 · Cited by 142
“Except delaying the age of onset, ApoE2 even decreases the risk of developing Alzheimer's disease (Corder et al., 1994).”
Epistatic effect of APP717 mutation and apolipoprotein E genotype in familial Alzheimer's disease
Sorbi, S., Nacmias, B., Forleo, P., Piacentini, S., Latorraca, S., & Amaducci, L. (1995) · Annals of Neurology · doi:10.1002/ana.410380120 · Cited by 109
APOE is a major susceptibility gene for Alzheimer’s disease
Roses, A. D., & Saunders, A. M. (1994) · Current Opinion in Biotechnology · doi:10.1016/0958-1669(94)90091-4 · Cited by 108
Self-citationCommon germline variants of the human APOE gene modulate melanoma progression and survival
Ostendorf, B. N., Bilanovic, J., Adaku, N., Tafreshian, K. N., Tavora, B., Vaughan, R. D., & Tavazoie, S. F. (2020) · Nature Medicine · doi:10.1038/s41591-020-0879-3 · Cited by 108
Reconsider Alzheimer's disease by the ‘calpain–cathepsin hypothesis’—A perspective review
Yamashima, T. (2013) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.02.004 · Cited by 116
A rapid and cost-effective method for genotyping apolipoprotein E gene polymorphism
Zhong, L., Xie, Y.-Z., Cao, T.-T., Wang, Z., Wang, T., Li, X., Shen, R.-C., Xu, H., Bu, G., & Chen, X.-F. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0069-4 · Cited by 106
“Conversely, the ε2 allele of APOE has a protective effect against AD [24].”
BackgroundAlzheimer disease: protective factors
Nourhashémi, F., Guyonnet, S., Andrieu, S., Ghisolfi, A., Ousset, P., Grandjean, H., Grand, A., Pous, J., Vellas, B. J., & Albaréde, J. L. (2000) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/71.2.643s · Cited by 125
Protein aggregation as a paradigm of aging
Lindner, A. B., & Démarez, A. (2009) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2009.06.005 · Cited by 128
Apolipoprotein E Genotype and Rate of Decline in Probable Alzheimer's Disease
Forno, G. D., Rasmusson, D. X., Brandt, J., Carson, K. A., Brookmeyer, R., Troncoso, J., & Kawas, C. H. (1996) · Archives of Neurology · doi:10.1001/archneur.1996.00550040085017 · Cited by 108
Alzheimer Aβ neurotoxicity: Promotion by antichymotrypsin, ApoE4; inhibition by Aβ-related peptides
Ma, J., Brewer, H. B., & Potter, H. (1996) · Neurobiology of Aging · doi:10.1016/0197-4580(96)00112-1 · Cited by 108
Germline genetic determination of cancer progression and survival
Ostendorf, B. N., Tafreshian, K. N., Adaku, N., Bilanovic, J., Tavora, B., & Tavazoie, S. F. (2019) · doi:10.1101/576181 · Cited by 108
“The APOE4 variant is the strongest monogenetic risk factor for Alzheimer’s disease, while APOE2 confers reduced risk for this disease (8, 9).”
BackgroundZhao, L., Gottesdiener, A. J., Parmar, M., Li, M., Kaminsky, S. M., Chiuchiolo, M. J., Sondhi, D., Sullivan, P. M., Holtzman, D. M., Crystal, R. G., et al. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.04.020 · Cited by 107
“By contrast, APOE2 is a protective allele reducing AD risk by approximately 50% and markedly delaying the age-of-onset (Corder et al., 1994; Farrer et al., 1997; Suri et al., 2013; Talbot et al., 1994; Yu et al., 2014).”
Astroglia as a cellular target for neuroprotection and treatment of neuro‐psychiatric disorders
Liu, B., Teschemacher, A. G., & Kasparov, S. (2017) · Glia · doi:10.1002/glia.23136 · Cited by 106
“Shortly afterwards it was reported that the other allele, APOE-e2, in contrast, is rather “protective” against AD (Corder et al., 1994).”
BackgroundHoogmartens, J., Cacace, R., & Van Broeckhoven, C. (2021) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1002/dad2.12155 · Cited by 104
Protein Homeostasis, Aging and Alzheimer’s Disease
Morawe, T., Hiebel, C., Kern, A., & Behl, C. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8246-0 · Cited by 107
“Several single nucleotide polymorphisms in apoE lead to alterations in the coding sequence and result in three common isoforms called apoE2, apoE3 and apoE4 with the E4 allele being an AD risk factor and E2 being protective [4–6].”
BackgroundComprehensive Search for Alzheimer Disease Susceptibility Loci in the APOE Region
Jun, G., Vardarajan, B. N., Buros, J., Yu, C.-E., Hawk, M. V., Dombroski, B. A., Crane, P. K., Larson, E. B., Mayeux, R., Haines, J. L., et al. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.2052 · Cited by 106
“Compared with the common APOE ε3 allele, ε4 increases the risk and lowers the age at onset (AAO) of AD in a dose-dependent fashion whereas the ε2 allele confers a protective benefit.(1,2) Although the frequency of ε4 varies among different ethnic groups, the ε4/AD association is evident in diverse populations,(3) with…”
BackgroundSelf-citationApolipoprotein E and Alzheimer disease
Huang, Y. (2006) · Neurology · doi:10.1212/01.wnl.0000192102.41141.9e · Cited by 106
APOE alters glucose flux through central carbon pathways in astrocytes
Williams, H. C., Farmer, B. C., Piron, M. A., Walsh, A. E., Bruntz, R. C., Gentry, M. S., Sun, R. C., & Johnson, L. A. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104742 · Cited by 105
Cerebral Small Vessel Disease and Alzheimer's Disease: A Review
Kim, H. W., Hong, J., & Jeon, J. C. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00927 · Cited by 116
“In Caucasian populations, individuals with the APOE ε4 allele were reported to have a 10-fold higher risk of developing AD than those without the APOE ε4 allele (42).”
BackgroundApolipoprotein E polymorphism and susceptibility to Alzheimer's disease.
Kamboh, M. I. (1995) · PubMed · Cited by 126
APOE genotype and gender effects on Alzheimer disease in 100 adults with Down syndrome
Lai, F., Kammann, E., Rebeck, G. W., Anderson, A., Chen, Y., & Nixon, R. A. (1999) · Neurology · doi:10.1212/wnl.53.2.331 · Cited by 105
Ordered-Subsets Linkage Analysis Detects Novel Alzheimer Disease Loci on Chromosomes 2q34 and 15q22
Scott, W. K., Hauser, E. R., Schmechel, D. E., Welsh-Bohmer, K. A., Small, G. W., Roses, A. D., Saunders, A. M., Gilbert, J. R., Vance, J. M., Haines, J. L., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/379083 · Cited by 109
“The APOE-4 allele increases risk and reduces age at onset of AD in a dose-dependent manner (Corder et al. 1993, 1994; Saunders et al. 1993; Strittmatter et al. 1993).”
BackgroundSelf-citationAPP Function and Lipids: A Bidirectional Link
Grimm, M. O. W., Mett, J., Grimm, H. S., & Hartmann, T. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00063 · Cited by 104
“In contrast, ApoEε2carriers have a reduced risk of developing AD (Corder et al., 1994).”
BackgroundBiochemical Markers in Alzheimer’s Disease
Rabbito, A., Dulewicz, M., Kulczyńska-Przybik, A., & Mroczko, B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21061989 · Cited by 104
“Conversely, particularly the APOE2 isoform is associated with a lower risk of developing AD [17].”
BackgroundREVIEW ARTICLE. MICROSATELLITES AND PCR GENOMIC ANALYSIS
Koreth, J., O’Leary, J. J., & McGee, J. O. (1996) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199603)178:3<284::aid-path470>3.0.co;2-9 · Cited by 104
The cell biology of APOE in the brain
Windham, I. A., & Cohen, S. (2024) · Trends in Cell Biology · doi:10.1016/j.tcb.2023.09.004 · Cited by 103
Genetics of Alzheimer's Disease. A Rapidly Evolving Field
Serretti, A., Olgiati, P., & De Ronchi, D. (2007) · Journal of Alzheimer's Disease · doi:10.3233/jad-2007-12108 · Cited by 103
“On the contrary having an APOE ε 2 allele has been associated with a lower risk for AD and a slightly older age at dementia onset [33,34].”
Genetic risk factors for spontaneous intracerebral haemorrhage
Carpenter, A., Singh, I. P., Gandhi, C. D., & Prestigiacomo, C. J. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.226 · Cited by 116
Population structure and linkage disequilibrium of a mini core set of maize inbred lines in China
Wang, R., Yu, Y., Zhao, J., Shi, Y., Song, Y., Wang, T., & Li, Y. (2008) · Theoretical and Applied Genetics · doi:10.1007/s00122-008-0852-x · Cited by 102
“Association mapping has been used extensively in human genetics (Corder et al. 1994; Templeton 1995).”
MethodImpact of Apolipoprotein E on Alzheimer’s Disease
Hauser, P., & Ryan, R. (2013) · Current Alzheimer Research · doi:10.2174/15672050113109990156 · Cited by 102
“Moreover, if apoE3 is considered neutral, apoE2 is regarded as protective against AD [23, 24].”
BackgroundPossible Causes of Alzheimer's Disease: Amyloid Fragments, Free Radicals, and Calcium Homeostasis
Hölscher, C. (1998) · Neurobiology of Disease · doi:10.1006/nbdi.1998.0193 · Cited by 102
Spires, T. L., & Hannan, A. J. (2005) · The FEBS Journal · doi:10.1111/j.1742-4658.2005.04677.x · Cited by 102
“Genetic risk factors also contribute to nonfamilial, or sporadic, AD. Inheritance of the apolipoprotein E (apoE) e4 allele increases the risk of contracting AD [103,104], while the e2 allele appears protective [ 105 ].”
BackgroundQuantitation of apoE Domains in Alzheimer Disease Brain Suggests a Role for apoE in Aß Aggregation
Cho, H. S., Hyman, B. T., Greenberg, S. M., & Rebeck, G. W. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.4.342 · Cited by 102
Epidemiology of the dementias: recent developments and new approaches.
van Duijn, C. M. (1996) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.60.5.478 · Cited by 102
Keeney, J. T.-R., Ibrahimi, S., & Zhao, L. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-150348 · Cited by 102
“ApoE2 is relatively rare, with only approximately 5% incidence, and it is recognized as a protective variant against AD [11, 20, 21].”
BackgroundLipid metabolism in Alzheimer’s disease
Liu, Q., & Zhang, J. (2014) · Neuroscience Bulletin · doi:10.1007/s12264-013-1410-3 · Cited by 101
“The APOE ε4 allele is the strongest risk factor for sporadic AD([75]).”
BackgroundCholesterol 24-Hydroxylation by CYP46A1: Benefits of Modulation for Brain Diseases
Petrov, A. M., & Pikuleva, I. A. (2019) · Neurotherapeutics · doi:10.1007/s13311-019-00731-6 · Cited by 118
Transgenic mouse models of Alzheimer’s disease
Janus, C., Chishti, M. A., & Westaway, D. (2000) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(00)00033-8 · Cited by 101
Apolipoprotein E, amyloid-beta, and neuroinflammation in Alzheimer’s disease
Dorey, E., Chang, N., Liu, Q. Y., Yang, Z., & Zhang, W. (2014) · Neuroscience Bulletin · doi:10.1007/s12264-013-1422-z · Cited by 116
Ohkubo, N., Mitsuda, N., Tamatani, M., Yamaguchi, A., Lee, Y.-D., Ogihara, T., Vitek, M. P., & Tohyama, M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m005070200 · Cited by 101
Farrer, L. A., Adrienne Cupples, L., Van Duijn, C. M., Kurz, A., Zimmer, R., Müller, U., Green, R. C., Clarke, V., Shoffner, J., Wallace, D. C., et al. (1995) · Annals of Neurology · doi:10.1002/ana.410380515 · Cited by 100
Self-citationGenetic Studies on Chromosome 12 in Late-Onset Alzheimer Disease
Wu, W. S. (1998) · JAMA · doi:10.1001/jama.280.7.619 · Cited by 100
Genetics of common cerebral small vessel disease
Bordes, C., Sargurupremraj, M., Mishra, A., & Debette, S. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-021-00592-8 · Cited by 99
Apolipoprotein E Genotype and Cerebral Amyloid Angiopathy‐related Hemorrhage
McCARRON, M. O., & NICOLL, J. A. R. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06366.x · Cited by 99
Duff, K. (2004) · Briefings in Functional Genomics and Proteomics · doi:10.1093/bfgp/3.1.47 · Cited by 99
Apolipoprotein E and lipid homeostasis in the etiology and treatment of sporadic Alzheimer's disease
Poirier, J., Miron, J., Picard, C., Gormley, P., Théroux, L., Breitner, J., & Dea, D. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.03.037 · Cited by 98
“…1996; Slooter et al., 1997), amyotrophic lateral sclerosis, or other type of neurode-generative disease (Hogh et al., 2000; Sorbi et al., 1995), apoE ε2 allele was found to be protective against several neurodegenerative diseases, including sporadic and familial late-onset AD (Corder et al., 1994).”
Kalaria, R. N., Maestre, G. E., Mahinrad, S., Acosta, D. M., Akinyemi, R., Alladi, S., Allegri, R., Arshad, F., Babalola, D. O., Baiyewu, O., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13836 · Cited by 123
Self-citationA Genome Survey for Novel Alzheimer Disease Risk Loci: Results at 10-cM Resolution
Zubenko, G. S., Hughes, H. B., Stiffler, J. S., Hurtt, M. R., & Kaplan, B. B. (1998) · Genomics · doi:10.1006/geno.1998.5306 · Cited by 102
Greasing the wheels of Aβ clearance in Alzheimer's Disease: The role of lipids and apolipoprotein E
Fan, J., Donkin, J., & Wellington, C. (2009) · BioFactors · doi:10.1002/biof.37 · Cited by 97
The effects of APOE-ε4 on the BOLD response
Trachtenberg, A. J., Filippini, N., & Mackay, C. E. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.03.009 · Cited by 104
Sleep apnea, APOE4 and Alzheimer's disease 20 years and counting?
Bliwise, D. L. (2002) · Journal of Psychosomatic Research · doi:10.1016/s0022-3999(02)00436-1 · Cited by 102
“Follow-up studies noted dose relationships between the number of E4 alleles and late-onset AD, whereas the presence of E2 allele appeared protective [3,4].”
BackgroundCerf, E., Gustot, A., Goormaghtigh, E., Ruysschaert, J.-M., & Raussens, V. (2011) · The FASEB Journal · doi:10.1096/fj.10-175976 · Cited by 92
“Conversely, the least frequent ε2 allele (5–10%) seems to have a protective effect regarding AD, as it is associated with the lowest risk and delays the onset of the disease (11).”
BackgroundECM receptors in neuronal structure, synaptic plasticity, and behavior
Kerrisk, M. E., Cingolani, L. A., & Koleske, A. J. (2014) · Progress in Brain Research · doi:10.1016/b978-0-444-63486-3.00005-0 · Cited by 96
“Conversely, the E2 allele of APOE serves a protective role in the development of AD (Corder et al., 1994).”
Couttas, T. A., Kain, N., Suchowerska, A. K., Quek, L., Turner, N. A., Fath, T., Garner, B., & Don, A. S. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.03.027 · Cited by 108
Amyloid β‐Protein, APOE Genotype and Head Injury
NICOLL, J. A. R., ROBERTS, G. W., & GRAHAM, D. I. (1996) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1996.tb34431.x · Cited by 96
Amyloid β-protein precursor: new clues to the genesis of Alzheimer's disease
Selkoe, D. J. (1994) · Current Opinion in Neurobiology · doi:10.1016/0959-4388(94)90014-0 · Cited by 114
TEC Monitoring by Using Satellite Positioning Systems
Jakowski, N. (1996) · elib (German Aerospace Center) · Cited by 117
α-Synuclein in Cerebrospinal Fluid of Alzheimer's Disease and Mild Cognitive Impairment
Korff, A., Liu, C., Ginghina, C., Shi, M., Zhang, J., & Initiative, F. T. A. D. N. (2013) · Journal of Alzheimer’s Disease · doi:10.3233/jad-130458 · Cited by 95
“To this end, studies have shown that subjects with the APOE 4/ 4 and 4/ 3 genotype are at increased risk for developing late onset AD, whereas the APOE 2 allele is considered protective [33, 34].”
Corlier, F., Hafzalla, G., Faskowitz, J., Kuller, L. H., Becker, J. T., Lopez, O. L., Thompson, P. M., & Braskie, M. N. (2018) · NeuroImage · doi:10.1016/j.neuroimage.2017.12.027 · Cited by 94
Genetics of Alzheimer’s Disease
Ridge, P. G., Ebbert, M. T. W., & Kauwe, J. S. K. (2013) · BioMed Research International · doi:10.1155/2013/254954 · Cited by 92
“It is not known, however, whether mitochondrial dysfunction is a cause or effect of NP aggregation [11].”
BackgroundApoE and Aβ1–42 Interactions: Effects of Isoform and Conformation on Structure and Function
Manelli, A. M., Stine, W. B., Van Eldik, L. J., & LaDu, M. J. (2004) · Journal of Molecular Neuroscience · doi:10.1385/jmn:23:3:235 · Cited by 95
Genetics of Age-Related Macular Degeneration
(2007) · Age-Related Macular Degeneration · doi:10.3109/9781420019865-8 · Cited by 95
Jendresen, C., Årskog, V., Daws, M. R., & Nilsson, L. N. G. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-0835-4 · Cited by 94
“The APOE4 allele increases the risk of AD by three- to fourfold [15, 16], while APOE2 is protective [17].”
BackgroundLeisure Activity in Old Age and Risk of Dementia: A 15-Year Prospective Study
Eriksson Sorman, D., Sundstrom, A., Ronnlund, M., Adolfsson, R., & Nilsson, L.-G. (2014) · The Journals of Gerontology Series B: Psychological Sciences and Social Sciences · doi:10.1093/geronb/gbt056 · Cited by 93
The ApoE receptors Vldlr and Apoer2 in central nervous system function and disease
Lane-Donovan, C., & Herz, J. (2017) · Journal of Lipid Research · doi:10.1194/jlr.r075507 · Cited by 94
“tive against AD development, while ApoE3, the most common allele, is considered to be risk neutral (77).”
BackgroundHippocampal atrophy rates and CSF biomarkers in elderly APOE 2 normal subjects
Chiang, G. C., Insel, P. S., Tosun, D., Schuff, N., Truran-Sacrey, D., Raptentsetsang, S. T., Jack, C. R., Aisen, P. S., Petersen, R. C., Weiner, M. W., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181ffe4d1 · Cited by 94
Association of Rare APOE Missense Variants V236E and R251G With Risk of Alzheimer Disease
Le Guen, Y., Belloy, M. E., Grenier-Boley, B., de Rojas, I., Castillo-Morales, A., Jansen, I., Nicolas, A., Bellenguez, C., Dalmasso, C., Küçükali, F., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2022.1166 · Cited by 93
“21 gnomAD22 database–derived information was used to filter out SNVs that met one of the following exclusion criteria23,24: (1) located in a low-complexity region, (2) located within common structural variants (MAF greater than 1%), (3) multiallelic SNVs with MAF greater than 1% for at least 2 alternate alleles, (4) l…”
Burke, S. L., Maramaldi, P., Cadet, T., & Kukull, W. (2016) · International Psychogeriatrics · doi:10.1017/s1041610216000405 · Cited by 92
Lee, G., Pollard, H. B., & Arispe, N. J. (2002) · Peptides · doi:10.1016/s0196-9781(02)00060-8 · Cited by 104
Moulard, B., Sefiani, A., Laamri, A., Malafosse, A., & Camu, W. (1996) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(96)00085-8 · Cited by 93
Functional Characterization of Apolipoprotein E Isoforms Overexpressed in Escherichia coli
Morrow, J. A., Arnold, K. S., & Weisgraber, K. H. (1999) · Protein Expression and Purification · doi:10.1006/prep.1999.1069 · Cited by 109
Biomarkers in Neurodegenerative Diseases
Jeromin, A., & Bowser, R. (2017) · Advances in Neurobiology · doi:10.1007/978-3-319-57193-5_20 · Cited by 92
Functional Roles of the Interaction of APP and Lipoprotein Receptors
Pohlkamp, T., Wasser, C. R., & Herz, J. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00054 · Cited by 92
“ApoE3 is the most abundant allele and understood as the neutral isoform with regards to ADphysiology, the least abundant isoform ApoE2 appears to be protective against AD (Corder et al., 1994; Conejero-Goldberg et al., 2014).”
BackgroundGeltinger, F., Schartel, L., Wiederstein, M., Tevini, J., Aigner, E. S., Felder, T. K., & Rinnerthaler, M. (2020) · Molecules · doi:10.3390/molecules25215053 · Cited by 100
“The APOE E4 allele is a strong genetic risk factor for late onset of AD [173], while the APOE E2 allele lowers risk [174] in comparison to the common APOE E3 allele.”
BackgroundBabiloni, C., Benussi, L., Binetti, G., Cassetta, E., Dal Forno, G., Del Percio, C., Ferreri, F., Ferri, R., Frisoni, G., Ghidoni, R., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20724 · Cited by 93
Taylor, X., Cisternas, P., You, Y., You, Y., Xiang, S., Marambio, Y., Zhang, J., Vidal, R., & Lasagna-Reeves, C. A. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01900-7 · Cited by 91
Litvinchuk, A., Huynh, T. V., Shi, Y., Jackson, R. J., Finn, M. B., Manis, M., Francis, C. M., Tran, A. C., Sullivan, P. M., Ulrich, J. D., et al. (2021) · Annals of Neurology · doi:10.1002/ana.26043 · Cited by 91
“6 fold relative to the ε3/ε3 genotype.(5) Apolipoprotein E (ApoE) has been reported to play a pivotal role in Aβ aggre-”
BackgroundYu, Y. W. ‐., Lin, C., Chen, S.-P., Hong, C., & Tsai, S. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01569-x · Cited by 91
Neural cell adhesion molecule L1: Signaling pathways and growth cone motility
Kamiguchi, H., & Lemmon, V. (1997) · Journal of Neuroscience Research · doi:10.1002/(sici)1097-4547(19970701)49:1<32::aid-jnr4>3.0.co;2-e · Cited by 138
Traumatic brain injury history is associated with earlier age of onset of Alzheimer disease
LoBue, C., Wadsworth, H., Wilmoth, K., Clem, M., Hart, J., Womack, K. B., Didehbani, N., Lacritz, L. H., Rossetti, H. C., & Cullum, C. M. (2017) · The Clinical Neuropsychologist · doi:10.1080/13854046.2016.1257069 · Cited by 90
Metadata
- Authors
- Corder, E. H., Saunders, A. M., Risch, N. J., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Rimmler, J. B., Locke, P. A., Conneally, P. M., Schmader, K. E., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A.
- Affiliations
- Duke University (US)
- Yale University (US)
- Massachusetts General Hospital (US)
- Indiana University School of Medicine (US)
- University of California, Los Angeles (US)
- Venue
- Nature Genetics
- Published
- 1994-06
- Volume
- 7
- Issue
- 2
- Pages
- 180-184
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W2090271811
- Cited by
- 1,920
- References
- 41
- Citations by year
- 2026: 45 · 2025: 77 · 2024: 78 · 2023: 59 · 2022: 66 · 2021: 76 · 2020: 76 · 2019: 58 · 2018: 62 · 2017: 58 · 2016: 75 · 2015: 55 · 2014: 63 · 2013: 68 · 2012: 66
- FWCI
- 54.52
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (NIA AG05128, U24AG021886)
- National Institute of Neurological Disorders and Stroke (P01NS026630, NINDS NS26630, NINDS NS531153)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- apolipoprotein E, APOE ε4, late-onset Alzheimer's disease, familial Alzheimer's disease, gene dosage, protective effect, sporadic Alzheimer's disease, genetic risk factors, APOE genotype
- MeSH terms
- Aged, Alleles, Alzheimer Disease, Apolipoproteins E, Female, Gene Frequency, Genotype, Humans, Male, Middle Aged, Risk Factors, Odds Ratio, Age of Onset
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.